Sapience Therapeutics, Inc.’s Post

#ASCO24 is a wrap! Thank you to the meeting organizers for recognizing Sapience's exciting science and providing a broad platform to share our ST101 clinical results in GBM. We enjoyed interacting with industry colleagues, clinical investigators, and patient groups, and it was an honor for our data to be accepted as an oral presentation. #ASCO24 #biotech #GBM

Here is a full recap from our Phase 2 ST101 results in GBM at #ASCO24 presented by Dr. Fabio Iwamoto, MD. Click below for the recap: https://lnkd.in/g-tVWaEr   Click here to access the ASCO slides: https://lnkd.in/gHiPgBm5 #ASCO24 #oncology #GBM

The results demonstrated with ST101 in this GBM study are very encouraging, given the poor prognosis associated with this brain cancer. With the data presented at #ASCO24 today, we believe that ST101 has the potential to be a well-tolerated treatment option for patients, and we look forward to its continued development in combination Phase 2 studies. #ASCO2024 #oncology #GBM

Did you know? More than any other cancer, brain tumors can have lasting and life-altering physical, cognitive, and psychological impacts. That's why we're dedicated to advancing therapies for patients facing challenging brain tumors. Join us in raising awareness by participating in #GoGrayinMay and help shed light on this debilitating disease. Learn more here: https://lnkd.in/g9tztgw8 #Biotechnology #Oncology #Glioblastoma #GBM #BTAM #GrayMay

Dr. Fabio Iwamoto, presenting author at #ASCO24, will give an oral presentation on ST101 in GBM on June 1, 2024. We invite you to attend this scientific session to learn more.    More details can be found here: https://lnkd.in/gKV2npZt   #ASCO24 #Oncology #Glioblastoma #GBM

Attending #ASCO24? The Sapience team is excited to share that we will present new clinical and biomarker data from our ST101 Phase 2 study in glioblastoma during an oral presentation at #ASCO24.   Learn more here: https://lnkd.in/gcX-zh-d   #ASCO24 #Oncology #Glioblastoma #GBM Abi Vainstein-Haras

Did you know? An estimated 18,870 people will die from a malignant brain tumor in 2024. Sapience Therapeutics, Inc. is dedicated to creating new therapies to extend life and quality of life for brain tumor patients. This #BrainTumorAwarenessMonth, join the Sapience Team and #GoGrayinMay to take action by raising awareness to conquer and cure brain tumors. Learn more here: https://lnkd.in/g9tztgw8 #Biotechnology #Oncology #Glioblastoma #GBM #BTAM #GrayMay #GoGrayInMay

Did you know? Nearly 95,000 people were diagnosed with a primary brain tumor in 2023. At Sapience Therapeutics, Inc., we're on a mission to change the treatment paradigm and provide hope to patients with our SPEARs™, peptide therapeutics that cross the blood-brain barrier. This #BrainTumorAwarenessMonth, join the Sapience Team and #GoGrayinMay to take action by raising awareness to conquer and cure brain tumors.    Learn more here: https://lnkd.in/g9tztgw8   #Biotechnology #Oncology #Glioblastoma #GBM #BTAM #GrayMay #GoGrayInMay

The Sapience Therapeutics, Inc. team is excited to share that we will present new clinical efficacy and biomarker data from our Phase 2 clinical study of ST101 in glioblastoma during an oral presentation at #ASCO24.    Learn more here: https://bit.ly/4b42J41   #Biotechnology #Oncology #glioblastoma #gbm